Artikel dengan mandat akses publik - Samar A HegazyPelajari lebih lanjut
Tersedia di suatu tempat: 13
IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma
JD Bard, P Gelebart, M Anand, Z Zak, SA Hegazy, HM Amin, R Lai
The American journal of pathology 175 (2), 825-834, 2009
Mandat: US National Institutes of Health, Canadian Institutes of Health Research
Genetic Screening for Synthetic Lethal Partners of Polynucleotide Kinase/Phosphatase: Potential for Targeting SHP-1–Depleted Cancers
TR Mereniuk, RA Maranchuk, A Schindler, J Penner-Chea, GK Freschauf, ...
Cancer research 72 (22), 5934-5944, 2012
Mandat: Canadian Institutes of Health Research
Aberrant expression and biological significance of Sox2, an embryonic stem cell transcriptional factor, in ALK-positive anaplastic large cell lymphoma
P Gelebart, SA Hegazy, P Wang, KM Bone, M Anand, D Sharon, M Hitt, ...
Blood cancer journal 2 (8), e82-e82, 2012
Mandat: Canadian Institutes of Health Research
Cysteine-rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients’ prognosis
S Al Bashir, M Alshalalfa, SA Hegazy, M Dolph, B Donnelly, TA Bismar
Journal of hematology & oncology 7, 1-11, 2014
Mandat: Prostate Cancer Canada
Ankyrin G expression is associated with androgen receptor stability, invasiveness, and lethal outcome in prostate cancer patients
T Wang, H Abou-Ouf, SA Hegazy, M Alshalalfa, K Stoletov, J Lewis, ...
Journal of Molecular Medicine 94, 1411-1422, 2016
Mandat: Prostate Cancer Canada
High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer
A Box, M Alshalalfa, SA Hegazy, B Donnelly, TA Bismar
Tumor Biology 37, 12287-12299, 2016
Mandat: Prostate Cancer Canada
Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification
TA Bismar, S Hegazy, Z Feng, D Yu, B Donnelly, N Palanisamy, BJ Trock
Journal of cancer research and clinical oncology 144, 2117-2125, 2018
Mandat: Prostate Cancer Canada
Fusion tyrosine kinase NPM-ALK deregulates MSH2 and suppresses DNA mismatch repair function: novel insights into a potent oncoprotein
LC Young, KM Bone, P Wang, F Wu, BA Adam, S Hegazy, P Gelebart, ...
The American journal of pathology 179 (1), 411-421, 2011
Mandat: Canadian Institutes of Health Research
microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients
A Bakkar, M Alshalalfa, LF Petersen, H Abou-Ouf, A Al-Mami, SA Hegazy, ...
Molecular biology reports 43, 229-240, 2016
Mandat: Canadian Cancer Society, Canadian Institutes of Health Research, Prostate …
ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients
A Almami, SA Hegazy, A Nabbi, M Alshalalfa, A Salman, H Abou-Ouf, ...
Tumor Biology 37, 9731-9738, 2016
Mandat: Prostate Cancer Canada
The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor …
SA Hegazy, P Wang, M Anand, RJ Ingham, P Gelebart, R Lai
Journal of Biological Chemistry 285 (26), 19813-19820, 2010
Mandat: Canadian Institutes of Health Research
The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy
KC Huang, M Alshalalfa, SA Hegazy, M Dolph, B Donnelly, TA Bismar
Cancer Biology & Therapy 15 (9), 1120-1128, 2014
Mandat: Prostate Cancer Canada
Disheveled proteins promote cell growth and tumorigenicity in ALK-positive anaplastic large cell lymphoma
SA Hegazy, A Alshareef, P Gelebart, M Anand, H Armanious, RJ Ingham, ...
Cellular signalling 25 (1), 295-307, 2013
Mandat: Canadian Institutes of Health Research
Informasi terbitan dan pendanaan ditentukan secara otomatis oleh program komputer